IL145526A0 - Compositions and methods for effecting the levels of high density lipoprotein (hdl) chloesterol and apolipoprotein ai, very low density lipopritein (vldl) cholesterol and low density lipoprotein (ldl) cholesterol - Google Patents
Compositions and methods for effecting the levels of high density lipoprotein (hdl) chloesterol and apolipoprotein ai, very low density lipopritein (vldl) cholesterol and low density lipoprotein (ldl) cholesterolInfo
- Publication number
- IL145526A0 IL145526A0 IL14552600A IL14552600A IL145526A0 IL 145526 A0 IL145526 A0 IL 145526A0 IL 14552600 A IL14552600 A IL 14552600A IL 14552600 A IL14552600 A IL 14552600A IL 145526 A0 IL145526 A0 IL 145526A0
- Authority
- IL
- Israel
- Prior art keywords
- cholesterol
- low density
- density lipoprotein
- lipopritein
- chloesterol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
- C12N9/20—Triglyceride splitting, e.g. by means of lipase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/277,401 US7008776B1 (en) | 1996-12-06 | 1999-03-26 | Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol |
PCT/US2000/007870 WO2000057837A2 (en) | 1999-03-26 | 2000-03-24 | Compositions and methods for effecting the levels of cholesterol |
Publications (1)
Publication Number | Publication Date |
---|---|
IL145526A0 true IL145526A0 (en) | 2002-06-30 |
Family
ID=23060703
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL14552600A IL145526A0 (en) | 1999-03-26 | 2000-03-24 | Compositions and methods for effecting the levels of high density lipoprotein (hdl) chloesterol and apolipoprotein ai, very low density lipopritein (vldl) cholesterol and low density lipoprotein (ldl) cholesterol |
IL145526A IL145526A (en) | 1999-03-26 | 2001-09-20 | Method for diagnosing predispositions to low hdl cholesterol and apolipoprotein ai and method for determining inhibition of enzymotic reaction between lipg and hdl or vldl or ldl |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL145526A IL145526A (en) | 1999-03-26 | 2001-09-20 | Method for diagnosing predispositions to low hdl cholesterol and apolipoprotein ai and method for determining inhibition of enzymotic reaction between lipg and hdl or vldl or ldl |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1171078A4 (en) |
JP (1) | JP2002540127A (en) |
KR (2) | KR20050044812A (en) |
AU (1) | AU776684B2 (en) |
BR (1) | BR0009333A (en) |
CA (1) | CA2363486C (en) |
HK (1) | HK1043309A1 (en) |
IL (2) | IL145526A0 (en) |
MX (1) | MXPA01009727A (en) |
NO (2) | NO331779B1 (en) |
NZ (2) | NZ514350A (en) |
WO (1) | WO2000057837A2 (en) |
ZA (1) | ZA200107598B (en) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7507808B2 (en) * | 2002-12-12 | 2009-03-24 | Isis Pharmaceuticals, Inc. | Modulation of endothelial lipase expression |
US8288354B2 (en) | 2005-12-28 | 2012-10-16 | The Scripps Research Institute | Natural antisense and non-coding RNA transcripts as drug targets |
WO2010065792A2 (en) | 2008-12-04 | 2010-06-10 | Curna, Inc. | Treatment of erythropoietin (epo) related diseases by inhibition of natural antisense transcript to epo |
EP2370582B1 (en) | 2008-12-04 | 2017-05-10 | CuRNA, Inc. | Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene |
ES2600781T3 (en) | 2008-12-04 | 2017-02-10 | Curna, Inc. | Treatment for diseases related to vascular endothelial growth factor (vegf) by inhibiting natural antisense transcripts of vegf |
ES2762610T3 (en) | 2009-02-12 | 2020-05-25 | Curna Inc | Treatment of diseases related to brain-derived neurotrophic factor (BDNF) by inhibition of natural antisense transcript for BDNF |
US9464287B2 (en) | 2009-03-16 | 2016-10-11 | Curna, Inc. | Treatment of nuclear factor (erythroid-derived 2)-like 2 (NRF2) related diseases by inhibition of natural antisense transcript to NRF2 |
CN102549159B (en) | 2009-03-17 | 2016-08-10 | 库尔纳公司 | By suppressing to treat the disease that DLK1 is correlated with for the natural antisense transcript of δ sample 1 congener (DLK1) |
CN103223177B (en) | 2009-05-06 | 2016-08-10 | 库尔纳公司 | By suppression therapy lipid transfer and the metabolic gene relevant disease of the natural antisense transcript for lipid transfer and metabolic gene |
CN102803492B (en) | 2009-05-06 | 2016-06-29 | 库尔纳公司 | TTP relevant disease is treated for the natural antisense transcript of triple four proline (TTP) by suppression |
CA3185821A1 (en) | 2009-05-08 | 2010-11-11 | Curna, Inc. | Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family |
EP2432881B1 (en) | 2009-05-18 | 2017-11-15 | CuRNA, Inc. | Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor |
CA2762987A1 (en) | 2009-05-22 | 2010-11-25 | Joseph Collard | Treatment of transcription factor e3 (tfe3) and insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to tfe3 |
JP5960049B2 (en) | 2009-05-28 | 2016-08-02 | クルナ・インコーポレーテッド | Treatment of antiviral gene-related diseases by suppression of natural antisense transcripts against antiviral genes |
JP6128846B2 (en) | 2009-06-16 | 2017-05-17 | クルナ・インコーポレーテッド | Treatment of PON1 gene-related diseases by suppression of natural antisense transcripts against paraoxonase (PON1) |
US20120171170A1 (en) | 2009-06-16 | 2012-07-05 | Opko Curna, Llc | Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene |
EP2446036B1 (en) | 2009-06-24 | 2017-03-01 | CuRNA, Inc. | Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2 |
CN102482672B (en) | 2009-06-26 | 2016-11-09 | 库尔纳公司 | By suppressing the natural antisense transcript treatment Down syndrome gene-associated diseases of Down syndrome gene |
JP2013500017A (en) | 2009-07-24 | 2013-01-07 | カッパーアールエヌエー,インコーポレイテッド | Treatment of sirtuin (SIRT) related diseases by blocking natural antisense transcripts to sirtuin (SIRT) |
CN102762731B (en) | 2009-08-05 | 2018-06-22 | 库尔纳公司 | By inhibiting to treat insulin gene (INS) relevant disease for the natural antisense transcript of insulin gene (INS) |
US9044493B2 (en) | 2009-08-11 | 2015-06-02 | Curna, Inc. | Treatment of Adiponectin related diseases by inhibition of natural antisense transcript to an Adiponectin |
WO2011022606A2 (en) | 2009-08-21 | 2011-02-24 | Curna, Inc. | Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip |
WO2011031482A2 (en) | 2009-08-25 | 2011-03-17 | Curna, Inc. | Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap |
EP2480669B1 (en) | 2009-09-25 | 2017-11-08 | CuRNA, Inc. | Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity |
RU2639550C2 (en) | 2009-12-16 | 2017-12-21 | Курна, Инк. | Treatment of diseases connected with site-1 membrane-impacted peptidase of transcription factors (mbtps1), by inhibiting natural antisense transcript to mbtps1 |
CN102781480B (en) | 2009-12-23 | 2018-07-27 | 库尔纳公司 | UCP2 relevant diseases are treated by inhibiting the natural antisense transcript of uncoupling protein-3 (UCP2) |
KR101891352B1 (en) | 2009-12-23 | 2018-08-24 | 큐알엔에이, 인크. | Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf |
WO2011090741A2 (en) | 2009-12-29 | 2011-07-28 | Opko Curna, Llc | TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63 |
CA2785173A1 (en) | 2009-12-29 | 2011-07-28 | Curna, Inc. | Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1 |
US20120289583A1 (en) | 2009-12-31 | 2012-11-15 | Curna, Inc. | Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3) |
US8946181B2 (en) | 2010-01-04 | 2015-02-03 | Curna, Inc. | Treatment of interferon regulatory factor 8 (IRF8) related diseases by inhibition of natural antisense transcript to IRF8 |
EP2521785B1 (en) | 2010-01-06 | 2022-03-09 | CuRNA, Inc. | Inhibition of natural antisense transcript to a pancreatic developmental gene for use in a treatment of pancreatic developmental gene related diseases |
US9200277B2 (en) | 2010-01-11 | 2015-12-01 | Curna, Inc. | Treatment of sex hormone binding globulin (SHBG) related diseases by inhibition of natural antisense transcript to SHBG |
CA2786568A1 (en) | 2010-01-25 | 2011-07-28 | Curna, Inc. | Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1 |
JP5976548B2 (en) | 2010-02-22 | 2016-08-23 | カッパーアールエヌエー,インコーポレイテッド | Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related diseases by inhibition of natural antisense transcripts against PYCR1 |
CA2795145C (en) | 2010-04-02 | 2019-01-22 | Curna, Inc. | Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3 |
CA2795281A1 (en) | 2010-04-09 | 2011-10-13 | Curna, Inc. | Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21 |
RU2693462C2 (en) | 2010-05-03 | 2019-07-03 | Курна, Инк. | Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to sirtuin (sirt) |
TWI531370B (en) | 2010-05-14 | 2016-05-01 | 可娜公司 | Treatment of par4 related diseases by inhibition of natural antisense transcript to par4 |
JP5917497B2 (en) | 2010-05-26 | 2016-05-18 | カッパーアールエヌエー,インコーポレイテッド | Treatment of MSRA-related diseases by inhibition of natural antisense transcripts against methionine sulfoxide reductase A (MSRA) |
RU2585229C2 (en) | 2010-05-26 | 2016-05-27 | Курна, Инк. | Treatment of diseases associated with atonal homolog 1 (aton1) by inhibiting natural antisense transcript of gene aton1 |
DK2585596T3 (en) | 2010-06-23 | 2021-04-06 | Curna Inc | TREATMENT OF VOLTAGE REGULATED SODIUM CHANNEL ALPHA SUBSIDY (SCNA) -RELATED DISEASES IN INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO SCNA |
JP5998131B2 (en) | 2010-07-14 | 2016-09-28 | カッパーアールエヌエー,インコーポレイテッド | DISCSLARGEHOMOLOG (DLG) Treatment of DLG-related diseases by inhibition of natural antisense transcripts on DLG1 |
EP2625274B1 (en) | 2010-10-06 | 2017-07-19 | CuRNA, Inc. | Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4 |
US9222088B2 (en) | 2010-10-22 | 2015-12-29 | Curna, Inc. | Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA |
US10000752B2 (en) | 2010-11-18 | 2018-06-19 | Curna, Inc. | Antagonat compositions and methods of use |
RU2608493C2 (en) | 2010-11-23 | 2017-01-18 | Курна, Инк. | Treating diseases, associated with nanog, by inhibition of natural antisense nanog transcript |
TWI678375B (en) | 2011-06-09 | 2019-12-01 | 可娜公司 | Treatment of frataxin (fxn) related diseases by inhibition of natural antisense transcript to fxn |
CN103874486A (en) | 2011-09-06 | 2014-06-18 | 库尔纳公司 | Treatment of diseases related to alpha subunits of sodium channels, voltage-gated (scnxa) with small molecules |
HUE040179T2 (en) | 2012-03-15 | 2019-02-28 | Curna Inc | Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf |
CN102628060A (en) * | 2012-03-22 | 2012-08-08 | 北京济福霖生物技术有限公司 | Production method of low-fat milk |
JP6362268B2 (en) | 2012-11-05 | 2018-07-25 | 塩野義製薬株式会社 | Method for evaluating drug efficacy and screening method for EL activity inhibitory substance having therapeutic or preventive effect on diseases associated with EL activity |
RU2662673C2 (en) | 2013-03-14 | 2018-07-26 | Сионоги Энд Ко., Лтд. | Monoclonal antibody inhibiting enzymatic activity of endothelial lipase |
TWI688575B (en) | 2014-09-11 | 2020-03-21 | 日商塩野義製藥股份有限公司 | Humanized monoclonal antibody, inhibiting the enzymatic activity of vascular endothelial lipase |
AU2022214429A1 (en) | 2021-02-01 | 2023-09-14 | Regenxbio Inc. | Gene therapy for neuronal ceroid lipofuscinoses |
WO2023008337A1 (en) * | 2021-07-26 | 2023-02-02 | ピューロテックバイオ株式会社 | Anti-hepatitis b virus agent targeting host factor lipg |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0707638A4 (en) * | 1992-12-04 | 1998-05-20 | Innovir Lab Inc | Regulatable nucleic acid therapeutic and methods of use thereof |
KR100516561B1 (en) * | 1996-12-06 | 2005-09-22 | 아벤티스 파마슈티칼스 인크. | Polypeptides encoded by a human lipase-like gene, compositions and methods |
WO1999032611A1 (en) * | 1997-12-19 | 1999-07-01 | Progenitor, Inc. | A lipase expressed in endothelial cells and methods for its use |
-
2000
- 2000-03-24 MX MXPA01009727A patent/MXPA01009727A/en active IP Right Grant
- 2000-03-24 WO PCT/US2000/007870 patent/WO2000057837A2/en active IP Right Grant
- 2000-03-24 IL IL14552600A patent/IL145526A0/en unknown
- 2000-03-24 KR KR1020057005114A patent/KR20050044812A/en active Search and Examination
- 2000-03-24 JP JP2000607588A patent/JP2002540127A/en active Pending
- 2000-03-24 BR BR0009333-5A patent/BR0009333A/en not_active Application Discontinuation
- 2000-03-24 KR KR1020017012300A patent/KR100887164B1/en not_active IP Right Cessation
- 2000-03-24 AU AU39187/00A patent/AU776684B2/en not_active Ceased
- 2000-03-24 NZ NZ51435000A patent/NZ514350A/en not_active IP Right Cessation
- 2000-03-24 EP EP00918362A patent/EP1171078A4/en not_active Ceased
- 2000-03-24 NZ NZ531180A patent/NZ531180A/en not_active IP Right Cessation
- 2000-03-24 CA CA2363486A patent/CA2363486C/en not_active Expired - Fee Related
-
2001
- 2001-09-14 ZA ZA200107598A patent/ZA200107598B/en unknown
- 2001-09-20 IL IL145526A patent/IL145526A/en not_active IP Right Cessation
- 2001-09-25 NO NO20014657A patent/NO331779B1/en not_active IP Right Cessation
-
2002
- 2002-06-28 HK HK02104818.0A patent/HK1043309A1/en unknown
-
2010
- 2010-02-11 NO NO20100214A patent/NO331784B1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
BR0009333A (en) | 2002-01-08 |
CA2363486C (en) | 2012-12-18 |
KR20050044812A (en) | 2005-05-12 |
KR20020029651A (en) | 2002-04-19 |
AU776684B2 (en) | 2004-09-16 |
EP1171078A4 (en) | 2002-11-06 |
KR100887164B1 (en) | 2009-03-10 |
HK1043309A1 (en) | 2002-09-13 |
NO20014657L (en) | 2001-11-21 |
NO20100214L (en) | 2001-11-21 |
WO2000057837A2 (en) | 2000-10-05 |
WO2000057837A3 (en) | 2001-01-25 |
NO331779B1 (en) | 2012-03-26 |
NO20014657D0 (en) | 2001-09-25 |
NZ531180A (en) | 2005-06-24 |
EP1171078A2 (en) | 2002-01-16 |
WO2000057837A9 (en) | 2001-10-18 |
NZ514350A (en) | 2004-12-24 |
IL145526A (en) | 2010-11-30 |
NO331784B1 (en) | 2012-03-26 |
AU3918700A (en) | 2000-10-16 |
WO2000057837A8 (en) | 2001-09-27 |
MXPA01009727A (en) | 2002-07-22 |
ZA200107598B (en) | 2003-05-28 |
CA2363486A1 (en) | 2000-10-05 |
JP2002540127A (en) | 2002-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL145526A0 (en) | Compositions and methods for effecting the levels of high density lipoprotein (hdl) chloesterol and apolipoprotein ai, very low density lipopritein (vldl) cholesterol and low density lipoprotein (ldl) cholesterol | |
EE200300136A (en) | Compositions and methods for lowering plasma lipoprotein (a) levels and reducing risk factors for cardiovascular disease | |
EP1212065A4 (en) | Compositions and methods for raising hdl cholesterol levels | |
AU2002306930A1 (en) | Plasma processor and method for operating same | |
HUP0100388A3 (en) | Pharmaceutical compositions and methods for treating osteoporosis and lowering cholesterol | |
AU1856997A (en) | Method for raising hdl cholesterol levels | |
IL112593A0 (en) | Methods for inhibiting bone loss and lowering serum cholesterol | |
EP1292603B8 (en) | Methods and compositions for treating hepatitis c virus | |
MY121405A (en) | 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines | |
MY130670A (en) | 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines | |
MY121838A (en) | 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines | |
AU1296099A (en) | Methods and compositions for treating dermatoses | |
AU3531299A (en) | Novel 4-phenylpiperidines for the treatment of pruritic dermatoses | |
AU4446400A (en) | Method and apparatuses for plasma treatment | |
AU2003204024A1 (en) | Methods for quantitating high-density lipoprotein cholesterol | |
AU6274898A (en) | Bipolar vaporization apparatus and method for arthroscopy | |
AU2002221657A1 (en) | Method and system for preventing the spread of computer viruses | |
DE69931279D1 (en) | METHOD AND COMPOSITIONS FOR REDUCING THE CHOLESTEROL MIRROR IN PLASMA | |
AU3065999A (en) | Compositions and methods for treatment of asthma | |
AU3471400A (en) | Compositions and methods for controlled delivery of virus vectors | |
AU3074099A (en) | Method and composition for lowering low density lipoprotein cholesterol | |
AU2001268601A1 (en) | Methods and apparatus for reducing vibrations induced within fan assemblies | |
EP1089731A4 (en) | Compositions and methods for treating elevated blood cholesterol | |
AU1683801A (en) | Methods and compositions for modulating er-stress-induced cholesterol/triglyceride accumulation | |
AU4558799A (en) | Methods and compositions for generating recombinant adeno-associated virus vectors |